skip to Main Content

Our Mission

IBT Bioservices is the contract research division of Integrated BioTherapeutics, Inc. (IBT). IBT Bioservices offers a strong client-oriented research and development service focused on our area of expertise, infectious diseases. Our team has extensive experience in antiviral and antibacterial screening and model development.

Our Team

M. Javad Aman, PhD

Javad leads IBT and its innovative science programs. He is a distinguished researcher in viral and bacterial diseases with 75+ publications.

Gary Nabors, PhD

Gary heads IBT’s product development team to translate its discovery pipeline into practical solutions for infectious diseases. See Gary’s publication

Rick Holtsberg, PhD
VP, Manufacturing & Bioanalytics

Rick leads IBT Bioservices’ assay & protein services group and develops IBT’s biochemical reagent portfolio. See Rick’s publications.

Robin Douglas
VP, Programs & Operations

Robin leads IBT Bioservices with its state-of-the-art infectious disease research capabilities and strong customer service focus.

Hatice Karauzum_Webresln1280px_DSC_2652
Hatice Karauzum, PhD
Associate Director, Translational Research

Hati investigates bacterial pathogenesis and cellular immune responses. See Hati’s publications.

Agnes Chenine_WebRsln 1280px_
Agnes Chenine, PhD
Director, Antiviral Research

Agnes oversees the in vivo studies program for testing new therapies and vaccines in various rodent models. See Agnes’s publications.

Rajan Adhikari_2 edited
Rajan Adhikari, PhD
Associate Director, Bacterial Therapeutics

Rajan investigates bacterial pathogens and leads antibacterial vaccine and therapeutic development programs. See Rajan’s publications.

Sergey Shulenin_Webres 1280px_lDSC_2699
Sergey Shulenin, PhD
Assistant Director, Protein Chemistry
Sergey works on assay development and protein expression. See Sergey’s publications.
Hong Vu_WebRsln1280px_DSC_2675

Hong Vu

Manager, Analytical Assay Development

Hong leads IBT’s assay development, quality control testing and provides logistical support for IBT’s research and bioservice projects. See Hong’s publications.

Thomas Kort_WebRsln1280px_DSC_2630

Thomas Kort

Principal Scientist

Tom works on protein expression and custom scientific projects. See Tom’s publications.

Shweta Kailasan_webrsln_1280pxDSC_2619

Shweta Kailasan, PhD

Principal Scientist

Shweta leads IBT’s discovery program for antiviral and antibacterial vaccine & antibody therapeutics. Read Shweta’s publications.

Aru Venkatasubramaniam_WebRsln1280px_DSC_2665

Aru Venkatasubrananiam, PhD

Scientist III

Aru leads IBT’s Chemistry Manufacturing Controls activities in vaccine formulation, development of analytics and animal potency models. See Aru’s publications.


Haimi Shiferaw

Business Development Advisor

Haimi leads IBT Bioservices’ strategic growth, marketing, and customer management team.

Our Partner

Back To Top
Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.

Alpha (UK) – B. 1.1.7 / 501Y.V1

amino acid mutations: del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H

Beta (South Africa) – B.1.351

amino acid mutations: K417N, E484K, N501Y, D614G, A701V

Gamma (Brazil) – P.1

amino acid mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

Epsilon (Ca, USA) B.1.427

amino acid mutations: L452R, D614G

SARS-CoV-2 Parental Strain Wild Type (Wuhan)
SARS-CoV-2 D614G Variant

amino acid mutations: D614G

Epsilon (Ca, USA) B.1.429

amino acid mutations: S13I, W152C, L452R, D614G

SARS-CoV-2 Delta Variant

amino acid mutations: L452R, E484Q